Acute exacerbation of IPF (AE-IPF)
Bedside summary
An acute (< 1 month) clinically significant worsening of breathlessness in a patient with IPF (or other fibrotic ILD), with NEW bilateral ground-glass opacity / consolidation on HRCT superimposed on the fibrotic background, NOT fully explained by cardiac failure or fluid overload. It may be triggered (infection, aspiration, surgery/biopsy, drugs, pollution) or idiopathic, carries a very high in-hospital mortality (around 50%) and is a leading cause of death in IPF.
Red flags
- Rapidly rising oxygen requirement / refractory hypoxaemia
- Haemodynamic instability or multi-organ failure
- Need for ventilatory support (poor prognosis — triggers ceiling-of-care discussion)
- Features of a treatable trigger (infection, PE, heart failure) that must not be missed
Assessment
Differential diagnosis
- Pneumonia / viral LRTI (including influenza, COVID-19)
- Pulmonary embolism
- Acute heart failure / fluid overload
- Aspiration pneumonitis
- Drug-induced pneumonitis
- Pneumothorax
- Progression of fibrosis without DAD
Investigations
- HRCT chest — new bilateral ground-glass/consolidation on a background of fibrosis (defines the syndrome); compare with prior imaging.
- Exclude mimics: CTPA for PE, echocardiography/BNP for cardiac failure, respiratory viral PCR (incl. influenza, SARS-CoV-2), sputum/blood cultures, procalcitonin.
- ABG — degree of hypoxaemic (type 1) respiratory failure.
- FBC, U&E, CRP, LFTs, BNP, D-dimer; consider bronchoscopy/BAL to exclude infection if it will change management and the patient can tolerate it.
Management
- Treat as a respiratory emergency: high-flow oxygen; high-flow nasal oxygen (HFNO) is often preferred for comfort and oxygenation.
- Aggressively look for and treat a reversible trigger — start empirical antibiotics ± antivirals for suspected infection, treat PE, heart failure and aspiration.
- HIGH-DOSE CORTICOSTEROIDS are commonly used (e.g. IV methylprednisolone pulses) — widely practised but evidence is low-quality; decide case-by-case with respiratory/ILD input.
- Optimise supportive care: careful fluid balance, VTE prophylaxis, nutrition, treat cough and distressing breathlessness (opioids).
- Discuss ceiling of care EARLY: invasive mechanical ventilation generally has very poor outcomes in AE-IPF and is usually not appropriate — involve the patient, family and ILD/ICU teams; HFNO or NIV may bridge selected transplant candidates.
- Continue or (re)start an antifibrotic where appropriate and involve the transplant team urgently for eligible candidates.
- Integrate palliative care in parallel for symptom control and advance-care planning given the high mortality.
Drugs & doses
Disposition
Complications & pitfalls
- Progressive hypoxaemic respiratory failure and death (~50% in-hospital mortality)
- Nosocomial infection (compounded by steroids)
- Barotrauma / poor outcomes with invasive ventilation
- VTE
Exam pearls
- New bilateral ground-glass on top of fibrosis, not explained by the heart or fluid, in an IPF patient = acute exacerbation until proven otherwise.
- Always exclude infection, PE and heart failure first — they are treatable and can masquerade as, or trigger, AE-IPF.
- High-dose steroids are widely given but the evidence is weak; the biggest early win is finding and treating a trigger plus getting the ceiling-of-care conversation right.
- Intubation in AE-IPF is usually futile — reserve it, at most, as a bridge for a transplant candidate.
AE-IPF: acute (<1 month) worsening with new bilateral ground-glass on a fibrotic background, not from cardiac failure. High-flow oxygen, aggressively exclude and treat infection/PE/heart failure, high-dose steroids are commonly used (low-quality evidence), and discuss ceiling of care early — invasive ventilation is usually futile. Mortality is around 50%; involve ILD, ICU, transplant and palliative-care teams. Antibiotic doses per BNF (current edition); confirm choice in the in-app Antibiotic Dosing tool.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.